Omega Fund Management, LLC Q2 2025 Filing
Filed August 14, 2025
Portfolio Value
$154.4B
Holdings
13
Report Date
Q2 2025
Filing Type
13F-HR
All Holdings (13 positions)
| # | Stock | Shares | Value | % Portfolio | Type |
|---|---|---|---|---|---|
| 1 | BBNXBeta Bionics Inc. | 1,988,287 | $28.9B | 18.75% | |
| 2 | KMTSKestra Med Technologies Ltd. | 1,645,893 | $27.3B | 17.67% | |
| 3 | UPBUpstream Bio Inc. | 2,036,293 | $22.4B | 14.48% | |
| 4 | NUVBNuvation Bio | 11,042,728 | $21.5B | 13.94% | |
| 5 | BCAXBicara Therapeutics Inc. | 2,204,650 | $20.5B | 13.26% | |
| 6 | REPLReplimune Group | 1,975,203 | $18.3B | 11.88% | |
| 7 | LXEOLexeo Therapeutics | 1,184,636 | $4.8B | 3.08% | |
| 8 | —Ikena Oncology | 2,249,123 | $3.0B | 1.95% | |
| 9 | SANASana Biotechnology, Inc. | 843,750 | $2.3B | 1.49% | |
| 10 | ALMSAlumis Inc. | 653,223 | $2.0B | 1.27% | |
| 11 | ENGNenGene Holdings Inc. | 526,357 | $1.9B | 1.24% | |
| 12 | IMUXImmunic Inc. | 1,788,160 | $1.2B | 0.81% | |
| 13 | ENGNWenGene Holdings Inc. | 321,502 | $273.0M | 0.18% |